What you should know:
1. The transaction terms were not disclosed.
2. Covis Pharma CEO Michael Porter said the transaction will allow the company to build out its respiratory continuum of care and establish new therapeutic franchises.
3. Covis currently develops treatments for respiratory, cardiovascular, gastroenterology and central nervous system diseases.
More articles on surgery centers:
New York endoscopy center shifts ownership
Lowering the CRC screening age to 45: Pros and cons
Smart Medical launches new colonoscope in European market — 3 insights
